Blog

Aparito partners with Red Cross War Memorial Children’s Hospital and YaAzi for an innovative project, Digital and Drone Solution (DADs), to design an integrated digital healthcare framework for low-income chronic disease patients in South Africa.

The project sees Aparito and Red Cross War Memorial Children’s Hospital expand on their previous work (Precision Management (PM) of Epilepsy in South African Children) in using remote patient monitoring technology to improve treatment outcomes for paediatric epilepsy patients. 

Aparito works alongside YaAzi in the preliminary development of a digitised outpatient supply chain that combines remote patient monitoring technology with drone delivery of medication to ensure that communities are provided with more readily accessible healthcare. 

Aparito and Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) revolutionised ataxia studies by configuring the Aparito Atom5™ mobile app to monitor Ataxia symptoms at home using a validated SARA^home assessment.

This collaboration utilises the innovative video capture and analysis functionality of the Atom5™ platform!

The collaboration is about the development and further assessment of a new app displaying the SARA^home scale within Aparito’s flagship software platform Atom5™. This way SARA^home is made available to patients on iOS and Android and is currently available in English, German, Dutch and Portuguese. Throughout the cooperation, it was rolled out in multiple study sites in Europe, including the DZNE in Bonn and Melbourne, Australia. 

A main benefit of the SARA^home app is that it enables close monitoring of Ataxia symptoms within a significantly brief period of time: Ataxia symptoms can be highly variable within a single day, from day to day and week to week. Travel to clinical sites can be stressful and time-consuming for patients, also impacting on a patient’s performance while being assessed and often leading to missed insight into disease variability. 

A publication by Dr Marcus Grobe-Einsler et al (2020) in the Journal Movement Disorders demonstrated the validity and feasibility of SARA^home and the first data from the home application suggests that fluctuations in the severity of ataxia exceed the expected range! 

The partnership between Aparito and the University of Birmingham is an exciting opportunity to create innovative remote patient monitoring solutions across a variety of disease areas including one of our Success Stories, ePROs and eConsent for Treatment & Understanding of Long COVID (TLC).

This partnership will see the configuration of Aparito’s flagship software platform Atom5™ to assess patient quality of life and symptoms in clinical trials and routine NHS care. The partnership brings together international experts in patient-reported outcomes methodology, input from patients and clinicians, with cutting-edge and innovative technology.

The aim of the partnership is to co-develop multiple digital Patient-Reported Outcomes (PROs) for use in a wide range of disease groups to assess treatment safety and effectiveness from the patient perspective and enhance the patient experience of clinical trials and routine care. These data will support patient care and provide evidence to inform regulators and policymakers such as the Medicines and Healthcare Regulatory Agency (MHRA) and the National Institute for Health (NICE).

Working with the team at the University of Birmingham to provide a technology solution for PRiORiTy has highlighted how deeply clinicians care about the patient experience and how they can improve treatment within the patient cohort.

Having such an approachable and knowledgeable team has allowed the University of Birmingham to detail very specifically how we can adapt our Aparito Atom5™ technology to really change a patient’s life and we cannot wait to work with the team again on future projects.

Our Credentials

21 CFR Part 11 compliant

Cyber Essentials Plus

Crest

ePrivacy App

ISO 13485

ISO 27001

Would you like to partner with us? Contact us using the form below.